Progyny (NASDAQ:PGNY – Get Rating) issued an update on its third quarter 2022 earnings guidance on Thursday morning. The company provided EPS guidance of $0.02-$0.03 for the period, compared to the consensus EPS estimate of $0.06. The company issued revenue guidance of $190.00 million-$197.00 million, compared to the consensus revenue estimate of $192.00 million. Progyny also updated its FY 2022 guidance to $0.14-$0.19 EPS.
Progyny Stock Performance
NASDAQ PGNY traded up $11.38 on Friday, hitting $41.15. 3,469,925 shares of the stock were exchanged, compared to its average volume of 684,594. The firm has a market capitalization of $3.78 billion, a P/E ratio of 89.46, a P/E/G ratio of 21.71 and a beta of 1.85. The stock has a fifty day moving average price of $30.23 and a two-hundred day moving average price of $37.32. Progyny has a 52-week low of $25.67 and a 52-week high of $68.32.
Progyny (NASDAQ:PGNY – Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.04. Progyny had a net margin of 7.39% and a return on equity of 18.11%. The business had revenue of $195.00 million during the quarter, compared to analyst estimates of $190.51 million. During the same period last year, the business earned $0.19 EPS. Progyny's revenue was up 51.5% compared to the same quarter last year. Sell-side analysts expect that Progyny will post 0.17 earnings per share for the current fiscal year.
Insider Buying and Selling
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Yousif Capital Management LLC boosted its stake in Progyny by 1.1% during the first quarter. Yousif Capital Management LLC now owns 37,264 shares of the company's stock valued at $1,915,000 after buying an additional 392 shares during the last quarter. Captrust Financial Advisors boosted its position in shares of Progyny by 25.0% during the first quarter. Captrust Financial Advisors now owns 2,091 shares of the company's stock valued at $107,000 after purchasing an additional 418 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of Progyny by 6.4% in the 1st quarter. Prudential Financial Inc. now owns 10,603 shares of the company's stock worth $545,000 after purchasing an additional 637 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Progyny during the first quarter worth about $62,000. Finally, Parkside Financial Bank & Trust acquired a new stake in Progyny during the first quarter valued at approximately $70,000. 82.51% of the stock is owned by hedge funds and other institutional investors.
对冲基金和其他机构投资者最近买卖了该股的股票。Yousif Capital Management LLC在第一季度将其在Progyny的持股增加了1.1%。Yousif Capital Management LLC现在拥有37,264股该公司股票，价值1,915,000美元，上个季度又购买了392股。CapTrust Financial Advisors在第一季度将其在Progyny股票的头寸增加了25.0%。CapTrust Financial Advisors在上个季度额外购买了418股后，现在拥有2,091股该公司股票，价值10.7万美元。保诚金融第一季度将其在Progyny股票的持仓增加了6.4%。保诚金融现在持有10,603股该公司股票，价值545,000美元，该公司在上个季度又购买了637股。Lazard Asset Management LLC在第一季度收购了Progyny价值约62,000美元的新股。最后，Parkside Financial Bank&Trust在第一季度收购了Progyny的新股份，价值约为7万美元。82.51%的股票由对冲基金和其他机构投资者持有。
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
- Get a free copy of the StockNews.com research report on Progyny (PGNY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- Beyond Meat不是没有希望，而且它很便宜
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.